To investigate the role of mRBPs in immune evasion, we analyzed the effect of mRBPs on the survival of patients from the IMvigor210 cohort.[12] Several top‐hit mRBPs demonstrating a positive correlation with the hazard ratio (Figure 1A) have been identified as significant contributors to tumor immune evasion (e.g., SND1,[15] EIF3B,[16] and RBMS1[17]) as well as BLCA progression (e.g., YBX3,[18] EIF4B,[19] and AFF4[20]). Here, EIF3B is linked to bladder transitional cell carcinoma.